Charles Magness
Director/Board Member at Kineta One LLC
Net worth: 329 439 $ as of 2024-06-29
Profile
Charles L.
Magness was the founder of Illumigen Biosciences, Inc. (founded in 2000), Kineta, Inc. (Washington) (founded in 2007), and Kineta, Inc. (founded in 2008), where he held the title of President & Chief Operating Officer, President & Chief Executive Officer, and President & Chief Executive Officer, respectively.
Currently, he is a Director at Kineta One LLC.
Magness's former positions include President, Chief Executive Officer & Director at KPI Therapeutics, Inc., Principal at the University of Washington, and Principal at McDonnell Douglas Automation.
He received a doctorate degree from Lehigh University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
KINETA, INC.
5.06% | 2023-12-30 | 620,413 ( 5.06% ) | 329 439 $ | 2024-06-29 |
Charles Magness active positions
Companies | Position | Start |
---|---|---|
Kineta One LLC
Kineta One LLC Pharmaceuticals: MajorHealth Technology Kineta One LLC provides biotechnology services. The company is headquartered in Seattle, WA. | Director/Board Member | - |
Former positions of Charles Magness
Companies | Position | End |
---|---|---|
Illumigen Biosciences, Inc.
Illumigen Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Illumigen Biosciences, Inc. provides pharmaceutical research services. It develops human genetic mutations that provide roadmap for therapeutic drug mechanisms. The company's product IB657 helps to investigate the cause of apparent immunity to HCV infection. Illumigen Biosciences was founded by Dr. Charles Magness and Shawn Iadonato in 2000 and is located in Seattle, WA | Founder | 2006-12-31 |
KINETA, INC. | Chief Executive Officer | - |
KPI Therapeutics, Inc.
KPI Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology KPI Therapeutics, Inc. operates as a clinical stage biotechnology company, which develops first in class therapies for unmet medical needs in autoimmunity. It offers dalazatide, KPI-150, and KPI-190 for systemic autoimmune diseases including lupus; and CSP conopeptide for chronic pain. The company was founded in 2013 and is headquartered in Seattle, WA. | Chief Executive Officer | - |
McDonnell Douglas Automation | Corporate Officer/Principal | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Training of Charles Magness
Lehigh University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
KINETA, INC. | Health Technology |
Private companies | 5 |
---|---|
Kineta One LLC
Kineta One LLC Pharmaceuticals: MajorHealth Technology Kineta One LLC provides biotechnology services. The company is headquartered in Seattle, WA. | Health Technology |
Illumigen Biosciences, Inc.
Illumigen Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Illumigen Biosciences, Inc. provides pharmaceutical research services. It develops human genetic mutations that provide roadmap for therapeutic drug mechanisms. The company's product IB657 helps to investigate the cause of apparent immunity to HCV infection. Illumigen Biosciences was founded by Dr. Charles Magness and Shawn Iadonato in 2000 and is located in Seattle, WA | Health Technology |
McDonnell Douglas Automation | |
Kineta, Inc. (Washington)
Kineta, Inc. (Washington) Pharmaceuticals: MajorHealth Technology Kineta, Inc. engages in the development of novel immuno-therapies. It develops a pipeline of therapies that address critical unmet patient needs in oncology, chronic pain and biodefense. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Seattle, WA. | Health Technology |
KPI Therapeutics, Inc.
KPI Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology KPI Therapeutics, Inc. operates as a clinical stage biotechnology company, which develops first in class therapies for unmet medical needs in autoimmunity. It offers dalazatide, KPI-150, and KPI-190 for systemic autoimmune diseases including lupus; and CSP conopeptide for chronic pain. The company was founded in 2013 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Charles Magness